×
BioAtla Total Long Term Liabilities 2020-2024 | BCAB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BioAtla total long term liabilities from 2020 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
View More
BioAtla Total Long Term Liabilities 2020-2024 | BCAB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BioAtla total long term liabilities from 2020 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$127.1B
Gilead Sciences (GILD)
$114.2B
Bristol Myers Squibb (BMY)
$112.1B
CSL (CSLLY)
$91B
Regeneron Pharmaceuticals (REGN)
$89.7B
GSK (GSK)
$74.4B
Argenex SE (ARGX)
$35.2B
Alnylam Pharmaceuticals (ALNY)
$35.2B
Biogen (BIIB)
$25.4B
BioNTech SE (BNTX)
$25.4B
Illumina (ILMN)
$24.2B
Moderna (MRNA)
$19.9B
BeiGene (BGNE)
$19.7B
Incyte (INCY)
$15.6B
Genmab (GMAB)
$14.8B
Insmed (INSM)
$13B
Vaxcyte (PCVX)
$13B
BioMarin Pharmaceutical (BMRN)
$12.6B
Sarepta Therapeutics (SRPT)
$12.2B
Bio-Techne Corp (TECH)
$12B
Exelixis (EXEL)
$10.1B
Exact Sciences (EXAS)
$10.1B
QIAGEN (QGEN)
$10B
Revolution Medicines (RVMD)
$9.9B
Intra-Cellular Therapies (ITCI)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$8.2B
Ascendis Pharma (ASND)
$7.8B